Mepolizumab/omalizumabLack of efficacy following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1998卷 / 1期

关键词：

D O I：

10.1007/s40278-024-54140-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：296 / 296

相关论文

共 50 条

[21] ChlorhexidineLack of efficacy following off-label use: case report
Reactions Weekly, 2025, 2055 (1) : 96 - 96
[22] AtomoxetineVarious toxicities and lack of efficacy following off-label use
Reactions Weekly, 2024, 2000 (1) : 61 - 61
[23] HydroxychloroquineLack of efficacy following an off-label use: case report
Reactions Weekly, 2021, 1858 (1) : 182 - 182
[24] OcrelizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2025, 2055 (1) : 283 - 283
[25] MethylprednisoloneLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1902 (1) : 280 - 280
[26] Multiple drugsLack of efficacy and thyroiditis following off-label use
Reactions Weekly, 2023, 1988 (1) : 124 - 124
[27] Cyclophosphamide/Prednisone/ThalidomideLack of efficacy following off-label use
Reactions Weekly, 2024, 2016 (1) : 156 - 156
[28] EribulinLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1921 (1) : 135 - 135
[29] RuxolitinibLack of efficacy following off-label use: case report
Reactions Weekly, 2024, 2039 (1) : 502 - 502
[30] LorazepamLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1919 (1) : 354 - 354

← 1 2 3 4 5 →